|Bid||13.950 x 400|
|Ask||13.960 x 300|
|Day's range||13.820 - 14.350|
|52-week range||4.410 - 16.600|
|PE ratio (TTM)||-9.53|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||18.93|
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news.
Amicus Therapeutics CEO Crowley is optimistic about Trump's plans to work with the pharma industry, proposing change for good.